In patients with secondary hypogonadism who wish to preserve fertility, alternatives to testosterone therapy, such as human chorionic gonadotropin (hCG), selective estrogen receptor modulators (SERMs), and aromatase inhibitors (AIs), are available, although these options remain off-label and lack robust efficacy data [14]. This evidence concerns the gene ESR1 and hypogonadotropic hypogonadism.